

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/tcr-23-1876	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The Tumor Immune Dysfunction and Exclusion (TIDE) scores and chemosensitivity data to chemotherapeutic drugs between the two cuproptosis-related molecular subtypes of HCC in particular will be shared, because these have guiding significance for clinical treatment.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan and analytic code will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	The data will be permanently available.
7	To whom will you share the data?	Medical oncologists and liver surgeons who are interested in studies of hepatocellular carcinoma.
8	For what type of analysis or purpose?	For analysis to investigate the role of cuproptosis in hepatocellular carcinoma.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: czh11200095@163.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.